Want to see PMN full AI Analyst Report?
PMN Stock Chart & Stats
$12.20
$0.16(1.28%)
At close: 4:00 PM EDT
$12.20
$0.16(1.28%)
Day’s Range― - ―
52-Week Range$6.27 - $27.40
Previous CloseN/A
Volume4.70K
Average Volume (3M)75.89K
Market Cap
$130.12M
Enterprise Value$66.85
Total Cash (Recent Filing)$53.46M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Nov 18, 2026EPS Estimate
-1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.62
Shares Outstanding8,967,693
10 Day Avg. Volume133,844
30 Day Avg. Volume75,892
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.53
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$42.46Price Target Upside248.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-5.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash RunwayThe reported cash balance and runway through 2027 give ProMIS time to advance PRECISE-AD toward its next major catalyst without immediate financing pressure, supporting continued research and clinical execution over the medium term.
Debt-free Balance SheetZero reported debt limits fixed financial obligations and reduces near-term solvency risk. The stronger equity position also provides a more stable capital base, although it does not eliminate the need for future funding.
Differentiated Alzheimer’s PipelinePMN310’s oligomer-selective approach and favorable interim safety and biomarker findings could differentiate it from plaque-binding antibodies, particularly for APOE4 carriers, if later data confirm meaningful clinical benefit.
Bears Say
No Commercial RevenueProMIS remains pre-commercial, with no operating revenue to offset research and development costs. The large TTM loss leaves performance dependent on clinical progress and access to external capital rather than a self-funding business model.
Persistent Cash BurnHeavy ongoing cash consumption means the company must continue funding operations through its balance sheet or new financing. If development spending remains elevated, future equity issuance could dilute shareholders and shorten financial flexibility.
Clinical Efficacy Remains UnprovenThe current PMN310 evidence is limited to interim safety and biomarker observations, not demonstrated patient benefit. Failure to confirm efficacy in unblinded data could materially weaken the pipeline and the company’s strategic prospects.
ProMIS Neurosciences News
PMN FAQ
What was ProMIS Neurosciences Inc.’s price range in the past 12 months?
ProMIS Neurosciences Inc. lowest stock price was $6.27 and its highest was $27.40 in the past 12 months.
What is ProMIS Neurosciences Inc.’s market cap?
ProMIS Neurosciences Inc.’s market cap is $130.12M.
When is ProMIS Neurosciences Inc.’s upcoming earnings report date?
ProMIS Neurosciences Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 87 days.
How were ProMIS Neurosciences Inc.’s earnings last quarter?
ProMIS Neurosciences Inc. released its earnings results on Aug 13, 2026. The company reported -$1.28 earnings per share for the quarter, beating the consensus estimate of -$1.379 by $0.099.
Is ProMIS Neurosciences Inc. overvalued?
According to Wall Street analysts ProMIS Neurosciences Inc.’s price is currently Undervalued.
Does ProMIS Neurosciences Inc. pay dividends?
ProMIS Neurosciences Inc. does not currently pay dividends.
What is ProMIS Neurosciences Inc.’s EPS estimate?
ProMIS Neurosciences Inc.’s EPS estimate is -1.27.
How many shares outstanding does ProMIS Neurosciences Inc. have?
ProMIS Neurosciences Inc. has 8,967,693 shares outstanding.
What happened to ProMIS Neurosciences Inc.’s price movement after its last earnings report?
ProMIS Neurosciences Inc. reported an EPS of -$1.28 in its last earnings report, beating expectations of -$1.379. Following the earnings report the stock price went up 0.473%.
Which hedge fund is a major shareholder of ProMIS Neurosciences Inc.?
Currently, no hedge funds are holding shares in PMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProMIS Neurosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.46 (248.02% Upside)
$42.46 (248.02% Upside)
Blogger Sentiment
Bullish
PMN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 46.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $30.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-46.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
496.18%
Trailing 12-Months
Company Description
ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
PMN Earnings Call
Q2 2026
0:00 / 0:00
PMN Stock 12 Month Forecast
Average Price Target
$42.46
▲(248.02% Upside)